Christopher D Still1, Peter Benotti1, Tooraj Mirshahi2, Adam Cook1, G Craig Wood3. 1. Obesity Research Institute, Geisinger Clinic, Danville, Pennsylvania. 2. Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania. 3. Obesity Research Institute, Geisinger Clinic, Danville, Pennsylvania. Electronic address: cwood@geisinger.edu.
Abstract
BACKGROUND: DiaRem is a validated tool for predicting the likelihood of type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery. OBJECTIVES: The objective of this study was to determine if the addition of duration of T2D to DiaRem improves its ability to discriminate between patients with or without T2D remission and/or to reclassify presurgery patients into accurate risk groups. SETTING: Academic Medical Center. METHODS: This study included patients consented into a prospective registry of Roux-en-Y gastric bypass between July 2009 and November 2015 with known duration of T2D (n = 307). Electronic health record-derived duration of T2D was compared with patient reported duration of T2D in a subset of patients (n = 48). DiaRem2 was created using clinical variables from DiaRem and duration of T2D. Area under the curve and the net reclassification index were used to assess increased performance of DiaRem2. RESULTS: Self-reported duration of T2D was highly concordant with electronic health record-derived T2D duration (96% agreement). Early T2D remission occurred in 44% of patients. DiaRem2 included age, hemoglobin A1C, insulin medication use, and duration of T2D. DiaRem2 had a higher area under the curve than DiaRem (.876 versus .850, P = .026), reduced the number of remission risk groups from 5 down to 3, and reclassified patients from intermediate to either high or low remission groups (net reclassification index, P < .0001). CONCLUSIONS: DiaRem2 simplifies and improves the accuracy of assessing probability of T2M remission after Roux-en-Y gastric bypass. Self-reported duration of T2D is an acceptable surrogate for T2D duration derived from clinical data.
BACKGROUND: DiaRem is a validated tool for predicting the likelihood of type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery. OBJECTIVES: The objective of this study was to determine if the addition of duration of T2D to DiaRem improves its ability to discriminate between patients with or without T2D remission and/or to reclassify presurgery patients into accurate risk groups. SETTING: Academic Medical Center. METHODS: This study included patients consented into a prospective registry of Roux-en-Y gastric bypass between July 2009 and November 2015 with known duration of T2D (n = 307). Electronic health record-derived duration of T2D was compared with patient reported duration of T2D in a subset of patients (n = 48). DiaRem2 was created using clinical variables from DiaRem and duration of T2D. Area under the curve and the net reclassification index were used to assess increased performance of DiaRem2. RESULTS: Self-reported duration of T2D was highly concordant with electronic health record-derived T2D duration (96% agreement). Early T2D remission occurred in 44% of patients. DiaRem2 included age, hemoglobin A1C, insulin medication use, and duration of T2D. DiaRem2 had a higher area under the curve than DiaRem (.876 versus .850, P = .026), reduced the number of remission risk groups from 5 down to 3, and reclassified patients from intermediate to either high or low remission groups (net reclassification index, P < .0001). CONCLUSIONS:DiaRem2 simplifies and improves the accuracy of assessing probability of T2M remission after Roux-en-Y gastric bypass. Self-reported duration of T2D is an acceptable surrogate for T2D duration derived from clinical data.
Authors: Ali Aminian; Stacy A Brethauer; Sangeeta R Kashyap; John P Kirwan; Philip R Schauer Journal: Lancet Diabetes Endocrinol Date: 2013-12-12 Impact factor: 32.069
Authors: Simona Panunzi; Lena Carlsson; Andrea De Gaetano; Markku Peltonen; Toni Rice; Lars Sjöström; Geltrude Mingrone; John B Dixon Journal: Diabetes Care Date: 2015-12-01 Impact factor: 19.112
Authors: Manal M Hassan; Steven A Curley; Donghui Li; Ahmed Kaseb; Marta Davila; Eddie K Abdalla; Milind Javle; Dalia M Moghazy; Richard D Lozano; James L Abbruzzese; Jean-Nicolas Vauthey Journal: Cancer Date: 2010-04-15 Impact factor: 6.860
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Christopher D Still; G Craig Wood; Peter Benotti; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Anna Ibele; Jamie Seiler; Brian A Irving; Melisa P Celaya; Robin Blackstone; Glenn S Gerhard; George Argyropoulos Journal: Lancet Diabetes Endocrinol Date: 2014-01 Impact factor: 32.069
Authors: G Craig Wood; Xin Chu; Christina Manney; William Strodel; Anthony Petrick; Jon Gabrielsen; Jamie Seiler; David Carey; George Argyropoulos; Peter Benotti; Christopher D Still; Glenn S Gerhard Journal: BMC Med Inform Decis Mak Date: 2012-05-28 Impact factor: 2.796
Authors: Karianne Fjeld Løvaas; John G Cooper; Sverre Sandberg; Thomas Røraas; Geir Thue Journal: BMC Health Serv Res Date: 2015-12-15 Impact factor: 2.655
Authors: Kajsa Sjöholm; Lena M S Carlsson; Magdalena Taube; Carel W le Roux; Per-Arne Svensson; Markku Peltonen Journal: Diabetes Care Date: 2020-09-01 Impact factor: 19.112